Align Technology grew Q2 2026 revenue 4.3% to $1.06 billion on 7.4% higher clear aligner case volume, but a $38.7 million legal and UK VAT charge pushed operating income down 5.5% and net income down 13.1%.
Aligner volume did the work; a $38.7 million legal and tax charge took the profit
Align Technology's second quarter of 2026 splits cleanly in two. The operating business got better: clear aligner shipments rose 7.4% to 691,800 cases, gross margin — the share of revenue left after the direct cost of making and shipping the product — widened 1.8 percentage points to 71.7%, and gross profit grew $49.3 million on $43.7 million of extra revenue. Then a single expense line that did not exist a year ago, "Legal settlements and contingencies" of $38.7 million, absorbed almost all of that gain. Reported operating income fell 5.5% to $154.0 million and net income fell 13.1% to $108.3 million on revenue that rose 4.3% to $1,056.2 million.
Strip that charge out and operating income would have been roughly $192.7 million, up 18.2% year over year, at an 18.2% operating margin (operating margin = the share of revenue left after all running costs, before interest and tax) versus 16.1% a year ago. The reported 14.6% margin is the worse of the two numbers and it is the one that counts this quarter, but it does not describe how the aligner business actually performed.
Source: Align Technology Form 10-Q for the quarter ended June 30, 2026, filed August 5, 2026. "pp" = percentage points.
What the $38.7 million actually is
Two items sit in the legal line. The larger, $37.5 million, is a provision for United Kingdom value added tax. Align has argued for years that doctor-prescribed clear aligners are VAT-exempt "dental prostheses"; HMRC disagreed and assessed roughly $100 million covering October 2019 through May 2023, which Align had to pay up front in order to contest. A UK tribunal ruled in Align's favor in April 2025. On July 7, 2026 — after the quarter closed but before the filing — the Upper Tribunal reversed that decision and held that aligners are subject to VAT at the standard rate. Align recorded $37.5 million as of June 30, 2026 as "management's best estimate of the obligation as of the reporting date," says it will "exhaust all available appeals," and states plainly that the outcome "remains subject to significant uncertainty." The remaining $1.2 million is ordinary legal settlements. Year to date the line totals $69.3 million, because the first quarter carried $30.6 million of settlements of its own.
This is a cash-and-legal problem, not an operating one, but it is not a clean one-off either: the estimate is management's, the appeal is unresolved, and the legal question the tribunal answered is about the product itself rather than a specific past period.
Clear Aligner: all volume, almost no price
The $66.3 million of Clear Aligner revenue growth breaks down in the filing as $53 million from higher volume and $13 million from "favorable foreign exchange rates and price increases" combined. Revenue per case shipment — the closest thing the filing gives to an average selling price, or ASP — rose just 0.8%, from $1,250 to $1,260, and part of even that came from a weaker dollar rather than from charging more. Over the six-month period the mix drag is explicit: $102 million of volume gain and $49 million of currency help, against $26 million lost to "higher discounts and product mix shift to lower-priced countries and products."
That is the shape of the business right now. Align is selling more cases to more doctors — 89,200 submitting doctors versus 86,300, and utilization up from 7.5 to 7.8 cases per submitting doctor — but each case is worth about what it was worth a year ago, and the cases are increasingly coming from cheaper geographies and cheaper product configurations. Management says as much in its own trend discussion: it expects "a shift from certain products with higher average selling prices to those with lower ASPs" as it pushes streamlined configurations with fewer or no additional aligners.
Segment profitability nevertheless improved sharply: Clear Aligner operating margin reached 37.4% from 33.2%, driven by higher gross margin plus lower advertising and marketing spend, partly offset by higher employee costs and credit card fees. Note the composition of that gain — cutting marketing while volume grows works until it doesn't, and Align itself notes orthodontic starts have declined for four consecutive years, with some doctors shifting patients to traditional wires and brackets when demand softens.
The teen cohort, the segment most insulated from discretionary-spending swings because parents treat orthodontics as a health decision, grew 7.2% to 239,200 shipments — essentially in line with the 7.4% total, so there is no evident divergence between teen and adult demand this quarter.
Systems and Services: more scanners, less money
The iTero scanner and exocad software segment shrank 10.8% to $185.3 million, and the mechanics are worth reading carefully. Unit demand was not the problem: higher system volume added $11 million, and non-system sales plus currency added $8 million. The declines came from a $27 million "mix shift to lower-priced products" and $15 million of lower scanner wand sales. Customers are buying scanners — just cheaper ones, and they are not paying for wand upgrades.
Segment margins went the other way. Systems and Services gross margin jumped to 73.3% from 69.4% on tariff refunds and operational efficiencies, partly offset by those lower ASPs, and operating margin edged up to 41.9% from 41.3% on reduced advertising. A segment whose revenue falls 10.8% while its gross margin rises 3.9 points is being managed for profit, not for growth. Tariff refunds in particular are a timing benefit rather than a durable cost improvement, and the filing flags them as a contributor to the consolidated margin gain alongside the roll-off of accelerated depreciation (the accelerated charge, $15.6 million in the first half tied to manufacturing assets retired under the 2025 restructuring, cost $0.16 per diluted share year to date and has now materially finished).
Geography: the US shrank
Revenue booked in the United States fell 6.5% to $395.2 million while "Other International" rose 16.4% to $412.4 million and Switzerland — a booking entity for much of the international business, not an end market — rose 5.7% to $248.6 million. The filing attributes revenue "based on the location of where revenues are recognized by our legal entities," so this is not a clean read of end demand by region, and the disclosure gives no Americas/EMEA/APAC split. What it does show unambiguously is that the US legal entity, the one least helped by currency, is the one going backwards, while internationally recognized revenue — flattered by a weaker dollar, which management confirms "favorably impacted our revenues" this quarter — is doing the growing.
Below the operating line
Currency cut both ways. It helped revenue and hurt everything below operating income: other income (expense), net swung $17.6 million, from $7.6 million of income to a $10.0 million expense, "primarily due to an unfavorable impact from foreign exchange rates." The effective tax rate improved to 27.2% from 28.2% on jurisdictional mix. Diluted share count fell 1.5% to 71.5 million after $98 million of first-half buybacks, which softened the EPS decline slightly relative to the net income decline.
Cash generation was the quarter's quiet strength. First-half operating cash flow nearly doubled to $343.8 million from $181.3 million, and cash and equivalents ended at $1,103 million with no debt drawn on a $300 million revolver. Align deployed that cash into $100 million of additional equity in dental service organization Heartland Dental (carrying value now $281.7 million, still under 5% ownership), $70 million of convertible notes, and a $19 million tuck-in acquisition in the Systems and Services segment, while collecting $42 million from the sale of the Juarez, Mexico manufacturing facility.
Takeaway: Align is now a volume-and-cost story rather than a pricing story — clear aligner revenue per case rose 0.8% while cases rose 7.4%, and consolidated gross margin gained 1.8 points on tariff refunds, depreciation roll-off and lower marketing rather than on price. That combination produced an 18.2% operating margin before the legal charge, but it depends on inputs that either reverse (tariff refunds) or cannot be cut indefinitely (advertising), in a market where orthodontic starts have fallen four years running.
What to watch
The 10-Q contains no revenue or earnings guidance — Align provides that on its earnings calls, not in the filing. What management does commit to in writing:
Capital expenditure of $125–150 million for full-year 2026, against $66 million spent in the first half, so spending steps up in the back half.
Up to $200 million of buybacks over the six months from May 1, 2026, with $733 million remaining on the April 2025 authorization.
A new manufacturing plant in Hyderabad, India, announced during the quarter, operational in 2027, costing approximately $200 million in capital and operating spend over several years. Management does not expect a material short-term liquidity impact. Read alongside the Juarez disposal and the 4.9% headcount reduction to 20,435, this is a deliberate relocation of manufacturing toward the markets now supplying Align's unit growth.
Three legal outcomes land within the next several quarters and each is genuinely binary. The UK VAT appeal determines whether the $37.5 million provision is close to final or the start of a larger number. In the Straumann/ClearCorrect case, a jury on July 2, 2026 cleared Align of the antitrust, unfair-competition and patent-fraud counterclaims — a real win — but simultaneously found the four infringed multilayer-material patents invalid for lack of enablement, which means Align did not obtain what it sued for: an injunction against ClearQuartz aligners. Post-trial motions and appeals are being evaluated, and six inter partes reviews at the patent board are due no later than November 9, 2026. Against Angelalign, the Unified Patent Court's preliminary injunction on the "Live Now" treatment-planning feature survived appeal on July 8, 2026 (€20,000 per day or cease use), and the US International Trade Commission judge's initial determination — which could exclude Angelalign aligners from the US market entirely — is due November 20, 2026.
My read on trajectory: the underlying earnings power is better than the reported line implies, and the cash flow confirms it. But growth is coming almost entirely from units rather than from units plus price, and two of the three margin tailwinds this quarter (tariff refunds, the depreciation roll-off) do not repeat at the same size. Mid-single-digit revenue growth with high-single-digit case growth and flat ASPs is a defensible base case; the variance around it sits almost entirely in the legal calendar and in whether a lower-priced competitor is excluded from the US market in November or not.